This is further supported by a recent systematic review and meta-analysis demonstrating that a high Ki67 after neoadjuvant endocrine therapy is associated with worse survival outcomes in ER-positive/HER2-negative early breast cancer [27]. Here, MKI67 is linked to breast carcinoma.